Abstracts tagged "Biologics"

Abstract Number: 622 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Laura C Coates¹, Peter Nash², Tore Kvien³, Laure Gossec⁴, Philip J Mease⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Steffen Jugl⁸, Kunal Gandhi⁷, Corine Gaillez⁸ and Josef S. Smolen⁹, ¹University of Oxford, Leeds, Great Britain, ²University of Queensland, Brisbane, Australia, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Swedish Medical Center and University of Washington, Seattle, WA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
Background/Purpose: Very low disease activity (VLDA) or remission (REM) and alternatively, minimal disease activity (MDA) or low disease activity (LDA) are optimal targets to be…
Abstract Number: 1447 • 2017 ACR/ARHP Annual Meeting
Smoking Reduces Efficacy of Biologics Differently By Target Cytokines in Rheumatoid Arthritis
Kentaro Kuzuya¹, Yukihiko Saeki², Jun Hashimoto³, Shirou Oshima⁴, Masato Matsushita⁵, Souichirou Tuji⁴, Yoshinori Harada⁶, Maiko Yoshimura⁶, Satoru Teshigawara⁶ and Hidetoshi Matsuoka⁴, ¹Rheumatology and Allegology, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ²Dept of Clinical research, Osaka-Minami Medical Ctr, Osaka, Japan, ³Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ⁴Division of Rheumatology, Osaka-Minami Medical Ctr, Osaka, Japan, ⁵Rheumatology, Osaka-Minami Medical Ctr, Osaka, Japan, ⁶Osaka-Minami Medical Ctr, Kawachinagano, Japan
Background/Purpose: Biologiccs (Bio) have shown outstanding efficacy and became one of the most effective drugs in the treatment of RA. However, several issues remain, including…
Abstract Number: 1818 • 2017 ACR/ARHP Annual Meeting
Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study
S Bandyopadhyay¹, MA Maldonado¹, R Ammar¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Centre, Dallas, TX
Background/Purpose: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical practice requires treatment-specific predictive models,…
Abstract Number: 2523 • 2017 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Associated Factors for Liver Abnormalities in Psoriatic Arthritis: Resutls from a Longitudinal Observational Cohort
Rattapol Pakchotanon¹, Justine (Yang) Ye¹, Richard J. Cook², Vinod Chandran³ and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease which affects the skin and musculoskeletal system. PsA patients frequently suffer from comorbidities: cardiovascular disease, metabolic…
Abstract Number: 344 • 2017 ACR/ARHP Annual Meeting
Real World Clinical Trial Comparing the Patient Reported Outcomes Measurement Information System Short Forms and Profiles to CDAI Disease Classification in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Sergio Schwartzman², Shelly Kafka³, Dennis Parenti³, Shawn Black³, Stephen Xu⁴, Wayne Langholff⁴ and Clifton O. Bingham III⁵, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²Weill Cornell Medical College, New York, NY, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Patient (Pt) reported outcomes (PROs) play a role in overall disease evaluation, therapeutic response assessment and care of rheumatoid arthritis (RA) patients (Pts). The…
Abstract Number: 625 • 2017 ACR/ARHP Annual Meeting
Rapid Onset of Efficacy in Patients with Active Psoriatic Arthritis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase III Clinical Trials
Atul A. Deodhar¹, Kim A. Papp², Catherine Shuler³, So Young Park³ and Tore K. Kvien⁴, ¹Oregon Health & Science University, Portland, OR, ²K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rapid onset of clinical improvement is an important attribute of treatment success for patients with PsA. These analyses evaluate the speed of onset of…
Abstract Number: 1448 • 2017 ACR/ARHP Annual Meeting
Prospective, Intervention, Multicenter, Non-Inferiority Study of Utility of Therapeutic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases
Catalina Gómez Arango¹, Maria Luz Garcia Vivar², Eduardo Úcar Angulo¹, Iñigo Gorostiza³, Clara Eugenia Perez², Juan Ramon De Dios⁴, Belen Alvarez⁵, Ana Ruibal Escribano⁶, Claudia Stoye⁵, Margarida Vasques⁵, Joaquin Belzunegui Otano⁷, Antonio Escobar³, Ziortza Trancho⁸, Ainhoa Ruiz del Agua⁹, Lorena Del Rio⁹, Cristina Jorquera¹⁰, Antonio Martínez⁹ and Daniel Nagore⁹, ¹Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Research Unit, Basurto Univeristy Hospital, Bilbao, Spain, ⁴Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, ⁵Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁶Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ⁷Donostia University Hospital, San Sebastian, Spain, ⁸Unidad de Investigación, Hospital Universitario de Basurto, Bilbao, Spain, ⁹R&D, Progenika-Grifols, Derio, Spain, ¹⁰Hospital Universitario de Basurto, Bilbao, Spain
Background/Purpose: Adalimumab (ADL) tapering based on clinical assessment is an usual practice, especially in patients in remission. The objective of INGEBIO was to analyze how…
Abstract Number: 1827 • 2017 ACR/ARHP Annual Meeting
Comparison of Ixekizumab and Ustekinumab Efficacy in the Treatment of Nail Lesions of Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Data from a Phase 3 Trial
Pierre-Dominique Ghislain¹, Curdin Conrad², Yves Dutronc³, Carsten Henneges³, David Sandoval Calderon³, Myriam Vincent³, Liesbet Ghys³, Jolien de Gruijter³ and Peter C M van de Kerkhof⁴, ¹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³Eli Lilly and Company, Indianapolis, IN, ⁴Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: Nails are frequently involved in psoriasis and represent one of the most difficult to treat manifestations of the disease. This study evaluated the comparative…
Abstract Number: 2539 • 2017 ACR/ARHP Annual Meeting
The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis
Arthur Kavanaugh¹, Alice B Gottlieb², Akimichi Morita³, Joseph Merola⁴, Julie Birt⁵, Chen-Yen Lin⁵, Catherine Shuler⁵ and Diamant Thaçi⁶, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Dermatology, New York Medical College, Vallhalla, NY, ³Dept of Geriatric & Environmental Dermatology, Nagoya City Univ Medical School, Nagoya, Japan, ⁴Clinical Unit for Research Innovation & Trials, Harvard Medical School, Boston, MA, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein Campus Luebeck, Ratzeburger Allee, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease affecting peripheral and axial joints. For patients with active psoriasis, the added burden of skin…
Abstract Number: 362 • 2017 ACR/ARHP Annual Meeting
Patients’ Experiences and Attitudes about Non-Medical Switching of Biologics: Results from an Online Patient Survey
Amanda Teeple¹, Lorie A. Ellis², Laura Huff³, Chuck Reynolds³, Seth D. Ginsberg⁴, Leah McCormick Howard⁵, Danielle Walls⁶ and Jeffrey R. Curtis⁷, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ³Benfield | Arthur J. Gallagher & Co., Webster Groves, MO, ⁴Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, ⁵National Psoriasis Foundation, Portland, OR, ⁶BDJ Solutions, Melrose, MA, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Health insurance plan designs often have benefits that result in highly prescriptive patient (pt) treatment options that can result in switching of patient’s medications…
Abstract Number: 626 • 2017 ACR/ARHP Annual Meeting
Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
Désirée van der Heijde¹, Masato Okada², Chin H. Lee³, Catherine Shuler³, Suchitrita Rathmann³, Chen-Yen Lin³ and Philip J Mease⁴, ¹Leiden University Medical Center, Leiden, Netherlands, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, was shown to be superior to placebo (PBO) in clinical responses and inhibiting the progression of structural joint…
Abstract Number: 1449 • 2017 ACR/ARHP Annual Meeting
Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Clothilde Barral¹, David Hajage², Bruno Fautrel³, Pierre Lafforgue¹, Florence Tubach² and Thao Pham¹, ¹Rheumatology, APHM, Aix Marseille Univ, Marseille, France, ²APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ³Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France
Background/Purpose: Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there…
Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial
Joel Kremer¹, William F C Rigby², Nora Singer³, Christine Birchwood⁴, Darcy Gill⁴, William Reiss⁴, Jinglan Pei⁴ and Margaret Michalska⁴, ¹Albany Medical College, Albany, NY, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting
Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Laura C Coates¹, Proton Rahman², Eliofotisti Psaradellis³, Emmanouil Rampakakis³, Brendan Osborne⁴, Allen J Lehman⁵ and Francois Nantel⁴, ¹LIRMM, University of Leeds, Leeds, United Kingdom, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵Janssen Inc., Toronto, ON, Canada
Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…
Abstract Number: 51 • 2017 Pediatric Rheumatology Symposium
The real-world decisive reasons for drug-escalation and treatment results of synthetic and biological therapy in JIA
Joost Swart¹, Nico Wulffraat², Sytze de Roock³ and Pieter van Dijkhuizen⁴, ¹Pediatric Rheumatology/ Immunology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ²Wilhelmina Children’s Hospital, Utrecht, Netherlands, ³Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: We wondered if with our current physician based strategy we really do reach improvement within 3 months and inactive disease within 12 months in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].